p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma ; volume:38 ; number:1 ; day:14 ; month:6 ; year:2019 ; pages:1-16 ; date:12.2019
Journal of experimental & clinical cancer research ; 38, Heft 1 (14.6.2019), 1-16, 12.2019
- Creator
-
Giordano, Federica
Vaira, Valentina
Cortinovis, Diego
Bonomo, Sara
Goedmakers, Joyce
Brena, Federica
Cialdella, Annamaria
Ianzano, Leonarda
Forno, Irene
Cerrito, Maria Grazia
Giovannoni, Roberto
Ferri, Gian Luca
Tasciotti, Ennio
Vicent, Silve
Damarco, Francesco
Bosari, Silvano
Lavitrano, Marialuisa
Grassilli, Emanuela
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-019-1199-7
- URN
-
urn:nbn:de:101:1-2019111922442332955146
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.11.2025, 10:04 AM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Giordano, Federica
- Vaira, Valentina
- Cortinovis, Diego
- Bonomo, Sara
- Goedmakers, Joyce
- Brena, Federica
- Cialdella, Annamaria
- Ianzano, Leonarda
- Forno, Irene
- Cerrito, Maria Grazia
- Giovannoni, Roberto
- Ferri, Gian Luca
- Tasciotti, Ennio
- Vicent, Silve
- Damarco, Francesco
- Bosari, Silvano
- Lavitrano, Marialuisa
- Grassilli, Emanuela
- SpringerLink (Online service)
Other Objects (12)
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma
Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma
Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer
CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma
Regulation and therapeutic targeting of MTHFD2 and EZH2 in KRAS mutated human pulmonary adenocarcinoma
EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers
Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
Pancreatic Adenocarcinoma with Co-Occurrence of KRAS and EGFR Mutations: Case Report and Literature Review
An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma
Somatically mutated ABL 1 is an actionable and essential NSCLC survival gene
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma